Welcome to our dedicated page for Synlogic news (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic stock.
Synlogic, Inc. news has centered on financial results and corporate updates for a biopharmaceutical company that developed genetically engineered probiotic drug candidates. Synlogic designed, developed, and manufactured drug candidates using precision genetic engineering applied to well-characterized probiotics, including GI-restricted orally administered biopharmaceuticals.
Recurring updates have covered the discontinuation of Synpheny-3, the pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria, strategic-review activity, a limited-duration stockholder rights plan, Roche collaboration revenue, restructuring charges, and published data for SYNB1353 in classical homocystinuria.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.